Document is current

Article History

Received: 17 June 2024

Accepted: 15 October 2024

First Online: 7 November 2024

Declarations

:

: All authors declare some conflict of interest since La Roche-Posay funded this study. Moreover, Anne Laure Demessant-Flavigny, Leonor Prieto and Caroline Le Floc’h are L’Oreal Employees. In the last 36 months, existing conflict of interests were: Véronique Del Marmol have grants or contracts from BMS, MSD, Almirall and Sanofia; Josep Malvehy and Susana Puig from Abbvie, Almirall, Amgen, BMS, Biofrontera, Canfield, Cantabria, Fotofinder, GSK, ISDIN, La Roche Posay, Leo Pharma, MSD, MEDA, Novartis, Polychem, Roche and Sun Pharma. Véronique Del Marmol has received consulting fees from BMS, MSD, Sanofi, Merck, Almirall, Abbvie, Leo pharma, Pierre fabre, andNovartis. Josep Malvehy and Susana Puig have received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Roche Posay, Pierre-Fabre, Almirall and ISDIN; Jilliana Monnier from BMS, Pierre Fabre and Novartis; MP from ISDIN; Véronique Del Marmol from BMS, MSD,Sanofi, Sun pharma, Pierre fabre and Novartis. Josep Malvehy and Susana Puig received support for attending meetings and/or travel from Roche Posay, Pierre-Fabre, Almirall and ISDIN; Véronique Del Marmol from BMS, MSD, Pierre Fabre and Novartis; Josep Malvehy and Susana Puig participated on a Data Safety Monitoring Board Advisory Board for Pierre-Fabre, Almirall, SunPharma. Josep Malvehy and Susana Puig have stock options in Athena Tech of Dermavision.

: The study was approved in November 2019 by the Ethics Committee of Hospital Clínic de Barcelona, Spain (Nº HCB20190849). This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The patients who took part in the study have given written informed consent to the publication of their case details.